血小板生成素受体激动剂在血小板减少性疾病中应用的研究进展 |
| |
引用本文: | 郭妹,沈文怡,陆化. 血小板生成素受体激动剂在血小板减少性疾病中应用的研究进展[J]. 国际输血及血液学杂志, 2016, 0(1): 50-53. DOI: 10.3760/cma.j.issn.1673-419X.2016.01.009 |
| |
作者姓名: | 郭妹 沈文怡 陆化 |
| |
作者单位: | 210029,南京医科大学第一附属医院血液科 |
| |
基金项目: | National Natural Science Foundation of China(81400079),国家自然科学基金项目(81400079) |
| |
摘 要: | 血小板减少性疾病是常见的血液系统疾病,病因繁多,多见于原发免疫性血小板减少症(ITP)、骨髓衰竭性疾病、恶性血液病、慢性肝脏疾病,以及化疗引起的血小板减少症.目前,血小板生成素受体激动剂(TPORA)在各种血小板减少性疾病治疗中具有重要意义,可有效提高患者血小板计数,为血小板减少性疾病患者提供新的治疗方法.本文就TPORA在血小板减少性疾病中的临床应用和治疗安全性方面的研究进展进行综述.
|
关 键 词: | 受体,血小板生成素 血小板减少 贫血,再生障碍性 血液肿瘤 慢性病 肝疾病 |
Research progress on applications of thrombopoietin receptor agonist in thrombocytopenic diseases |
| |
Abstract: | Thrombocytopenic diseases are common diseases of the blood system diseases,which have various pathopoiesis factors.This clinical disorder can be found in the following diseases:primary immune thrombocytopenia (ITP),bone marrow failure diseases,hematologic malignancies,chronic liver disease and thrombocytopenia caused by chemotherapy and so on.Currently thrombopoietin receptor agonists (TPRA) play a significant role in improving the count of platelets effectively.This article reviews the research progress on clinical application and therapeutic safety of TPORA in thrombocytopenic diseases. |
| |
Keywords: | Receptors,thrombopoietin Thrombocytopenia Anemia,aplastic Hematologic neoplasms Chronic disease Liver diseases |
本文献已被 万方数据 等数据库收录! |
|